Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

BACKGROUND: Conventional cytotoxic agents and pazopanib are approved for advanced soft tissue sarcomas but have low response rates and modest survival benefits. Recently, immune checkpoint inhibitors have shown clinically meaningful activity. The combination of pazopanib and immunotherapy has shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Shalabh, Rastogi, Sameer, Shamim, Shamim Ahmed, Barwad, Adarsh, Sethi, Maansi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346343/
https://www.ncbi.nlm.nih.gov/pubmed/32670543
http://dx.doi.org/10.1186/s13569-020-00133-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346343/
https://www.ncbi.nlm.nih.gov/pubmed/32670543
http://dx.doi.org/10.1186/s13569-020-00133-9

Ejemplares similares